News Summary

Kardium, a company focused on treating atrial fibrillation, has achieved a significant milestone with its Globe System receiving pre-market approval from the FDA in the United States. This system is designed to treat the irregular heartbeat disorder affecting over 59 million people globally. Kardium’s CEO, Kevin Chaplin, hailed this approval as the most significant milestone in the life of the company.